INTRODUCTION
Fixed drug eruption (FDE) is a cutaneous drug reaction which recurs at the same site when the individual is exposed to the causative drug. The eruption is characterized by single or multiple round sharply demarcated erythematous-to-violaceous patches and rarely with generalized bullae resembling Stevens-Johnson syndrome or toxic epidermal necrolysis. The erythematous-to-violaceous hue usually improves over several days, resulting in a characteristic round hyperpigmented patch [1]. Although the culprit agent is usually a medication, such as a sulfa antibiotic or a nonsteroidal anti-inflammatory drug (NSAID), FDE has also been reported following vaccinations such as the influenza, yellow fever, and human papilloma virus vaccines [1-3].
To date, only five cases of FDE following COVID-19 vaccination have been reported, 3 following mRNA and 2 after adenoviral vector-based vaccines (Table 1 ) [4-8]. Here, we report a patient with generalized non-bullous fixed drug eruption following vaccination with the mRNA-based Pfizer-BioNTech COVID-19 vaccine.